RxDoctor Payments Data

Byron Ellis, MD

Cardiovascular Disease · Sugar Land, TXNPI 1821046780

Payments from drug & device makers

$143,731in general payments, 2019–2025

Across 813 payments — averaging $176.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$82K
  • CSL Behring$21K
  • Shockwave Medical, Inc$13K
  • Abbott$8K
  • Boehringer Ingelheim International GmbH$5K
  • Medtronic$3K
  • plus $12K from 48 others

What the payments were for

  • Consulting fees$3000%
  • Speaking & faculty fees$88,81075%
  • Travel & lodging$11,31610%
  • Food & beverage$17,28015%
  • Education$310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$143,731 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$700,373
Medicare patients
2,038
Services billed
7,219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban497$524,113
EliquisApixaban278$317,970
EntrestoSacubitril/Valsartan207$240,546
Repatha SureclickEvolocumab170$139,833
Praluent PenAlirocumab95$70,797
BrilintaTicagrelor76$55,561
FarxigaDapagliflozin Propanediol36$41,431
Metoprolol Succinate1,060$16,584
Valsartan345$14,913
Losartan Potassium1,053$13,852
Flecainide Acetate271$12,889
Nebivolol Hcl201$12,597
VascepaIcosapent Ethyl23$12,217
Rosuvastatin Calcium835$12,150
Prasugrel Hcl157$11,496

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$82,032$524,113497 claims
PfizerEliquis$623$317,970278 claims
NovartisEntresto$1,322$240,546207 claims
AstraZenecaBrilinta, Farxiga$803$96,992112 claims
Boehringer IngelheimJardiance$398$7,25211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →